Investors must take note of Century Therapeutics Inc’s (IPSC) performance last week, which was -1.68%.

A new trading day began on Friday, with Century Therapeutics Inc (NASDAQ: IPSC) stock price up 1.73% from the previous day of trading, before settling in for the closing price of $1.73. IPSC’s price has ranged from $1.28 to $5.51 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has dropped its sales by -14.25% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 23.48%. With a float of $32.41 million, this company’s outstanding shares have now reached $60.34 million.

In an organization with 165 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -488.98%, operating margin of -6517.58%, and the pretax margin is -6446.67%.

Century Therapeutics Inc (IPSC) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Century Therapeutics Inc is 61.74%, while institutional ownership is 26.49%. The most recent insider transaction that took place on Aug 05 ’24, was worth 1,960. In this transaction Chief Operations Officer of this company sold 1,073 shares at a rate of $1.83, taking the stock ownership to the 136,163 shares. Before that another transaction happened on Aug 05 ’24, when Company’s SVP Finance & Operations sold 289 for $1.83, making the entire transaction worth $528. This insider now owns 334,041 shares in total.

Century Therapeutics Inc (IPSC) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 23.48% per share during the next fiscal year.

Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators

Here are Century Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 73.09.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.86 in one year’s time.

Technical Analysis of Century Therapeutics Inc (IPSC)

Let’s dig in a bit further. During the last 5-days, its volume was 0.41 million. That was better than the volume of 0.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.80%. Additionally, its Average True Range was 0.21.

During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 7.62%, which indicates a significant decrease from 43.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.18% in the past 14 days, which was higher than the 95.19% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.1869, while its 200-day Moving Average is $3.0849. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $1.8333. Second resistance stands at $1.9067. The third major resistance level sits at $1.9933. If the price goes on to break the first support level at $1.6733, it is likely to go to the next support level at $1.5867. The third support level lies at $1.5133 if the price breaches the second support level.

Century Therapeutics Inc (NASDAQ: IPSC) Key Stats

With a market capitalization of 149.11 million, the company has a total of 84,501K Shares Outstanding. Currently, annual sales are 2,240 K while annual income is -136,670 K. The company’s previous quarter sales were 770 K while its latest quarter income was -31,210 K.